Blumenthal RS - Search Results

1

Spotlight on Icosapent Ethyl for Cardiovascular Risk Reduction: Evidence to Date.

Jia X, Koh S, Al Rifai M, Blumenthal RS, Virani SS. Jia X, et al. Among authors: blumenthal rs. Vasc Health Risk Manag. 2020 Jan 9;16:1-10. doi: 10.2147/VHRM.S210149. eCollection 2020. Vasc Health Risk Manag. 2020. PMID: 32021223 Free PMC article. Review.

2

ABCs of cardiovascular disease risk management.

Braunstein JB, Cheng A, Fakhry C, Nass CM, Vigilance C, Blumenthal RS. Braunstein JB, et al. Among authors: blumenthal rs. Cardiol Rev. 2001 Mar-Apr;9(2):96-105. doi: 10.1097/00045415-200103000-00008. Cardiol Rev. 2001. PMID: 11209148 Review.

3

A practical and evidence-based approach to cardiovascular disease risk reduction.

Gluckman TJ, Baranowski B, Ashen MD, Henrikson CA, McAllister M, Braunstein JB, Blumenthal RS. Gluckman TJ, et al. Among authors: blumenthal rs. Arch Intern Med. 2004 Jul 26;164(14):1490-500. doi: 10.1001/archinte.164.14.1490. Arch Intern Med. 2004. PMID: 15277278 Review.

4

Diets and cardiovascular disease: an evidence-based assessment.

Parikh P, McDaniel MC, Ashen MD, Miller JI, Sorrentino M, Chan V, Blumenthal RS, Sperling LS. Parikh P, et al. Among authors: blumenthal rs. J Am Coll Cardiol. 2005 May 3;45(9):1379-87. doi: 10.1016/j.jacc.2004.11.068. J Am Coll Cardiol. 2005. PMID: 15862406 Free article. Review.

5

Limitations of current cardiovascular disease risk assessment strategies in women.

Sibley C, Blumenthal RS, Merz CN, Mosca L. Sibley C, et al. Among authors: blumenthal rs. J Womens Health (Larchmt). 2006 Jan-Feb;15(1):54-6. doi: 10.1089/jwh.2006.15.54. J Womens Health (Larchmt). 2006. PMID: 16417419 No abstract available.

6

High density lipoprotein cholesterol: an evolving target of therapy in the management of cardiovascular disease.

Kapur NK, Ashen D, Blumenthal RS. Kapur NK, et al. Among authors: blumenthal rs. Vasc Health Risk Manag. 2008;4(1):39-57. doi: 10.2147/vhrm.2008.04.01.39. Vasc Health Risk Manag. 2008. PMID: 18629371 Free PMC article. Review.

7

The JUPITER and AURORA clinical trials for rosuvastatin in special primary prevention populations: perspectives, outcomes, and consequences.

Narla V, Blaha MJ, Blumenthal RS, Michos ED. Narla V, et al. Among authors: blumenthal rs. Vasc Health Risk Manag. 2009;5:1033-42. doi: 10.2147/vhrm.s6412. Epub 2009 Dec 29. Vasc Health Risk Manag. 2009. PMID: 20057896 Free PMC article. Review.

8

Screening for cardiovascular risk in asymptomatic patients.

Berger JS, Jordan CO, Lloyd-Jones D, Blumenthal RS. Berger JS, et al. Among authors: blumenthal rs. J Am Coll Cardiol. 2010 Mar 23;55(12):1169-1177. doi: 10.1016/j.jacc.2009.09.066. J Am Coll Cardiol. 2010. PMID: 20298922 Free article.

9

Clinical utility of rosuvastatin and other statins for cardiovascular risk reduction among the elderly.

Long SB, Blaha MJ, Blumenthal RS, Michos ED. Long SB, et al. Among authors: blumenthal rs. Clin Interv Aging. 2011;6:27-35. doi: 10.2147/CIA.S8101. Epub 2010 Dec 22. Clin Interv Aging. 2011. PMID: 21472089 Free PMC article. Review.

10

Evidence-based use of statins for primary prevention of cardiovascular disease.

Minder CM, Blaha MJ, Horne A, Michos ED, Kaul S, Blumenthal RS. Minder CM, et al. Among authors: blumenthal rs. Am J Med. 2012 May;125(5):440-6. doi: 10.1016/j.amjmed.2011.11.013. Epub 2012 Mar 2. Am J Med. 2012. PMID: 22387091 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

734 results

Search Page